BRISTOL-MYERS SQUIBB COMPANY Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount of $6.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Debt and Equity Securities › Equity Securities without Readily Determinable Fair Value, Annual Amount
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount · last filed 2026-07-30
- BRISTOL-MYERS SQUIBB COMPANY equity securities without readily determinable fair value, upward price adjustment, annual amount for the quarter ending 2026-06-30 was $6.00M, a 45.45% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY equity securities without readily determinable fair value, upward price adjustment, annual amount for the quarter ending 2026-03-31 was $171.00M.
- BRISTOL-MYERS SQUIBB COMPANY equity securities without readily determinable fair value, upward price adjustment, annual amount for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY equity securities without readily determinable fair value, upward price adjustment, annual amount for the quarter ending 2025-06-30 was $11.00M, a 0.00% change year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY equity securities without readily determinable fair value, upward price adjustment, annual amount for fiscal 2025 was $15.00M, a 58.33% decline from fiscal 2024.
- BRISTOL-MYERS SQUIBB COMPANY equity securities without readily determinable fair value, upward price adjustment, annual amount for fiscal 2024 was $36.00M, a 300.00% increase from fiscal 2023.
- BRISTOL-MYERS SQUIBB COMPANY equity securities without readily determinable fair value, upward price adjustment, annual amount for fiscal 2023 was $9.00M, a 88.75% decline from fiscal 2022.
- BRISTOL-MYERS SQUIBB COMPANY equity securities without readily determinable fair value, upward price adjustment, annual amount for fiscal 2022 was $80.00M, a 91.29% decline from fiscal 2021.
| Period end | Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount 3 month | Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount 3 month as first filed | Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount 6 month | Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount 6 month as first filed | Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount 9 month | Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount 9 month as first filed | Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount 12 month | Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $6.00M 10-Q · filed 2026-07-30 | $177.00M 10-Q · filed 2026-07-30 | ||||||
| 2026-03-31 | $171.00M 10-Q · filed 2026-04-30 | |||||||
| 2025-12-31 | $15.00M 10-K · filed 2026-02-11 | |||||||
| 2025-09-30 | $0.00 10-Q · filed 2025-10-30 | $11.00M 10-Q · filed 2025-10-30 | ||||||
| 2025-06-30 | $11.00M 10-Q · filed 2026-07-30 | $11.00M 10-Q · filed 2026-07-30 | ||||||
| 2025-03-31 | $0.00 10-Q · filed 2026-04-30 | |||||||
| 2024-12-31 | $36.00M 10-K · filed 2026-02-11 | |||||||
| 2024-09-30 | $15.00M 10-Q · filed 2025-10-30 | $36.00M 10-Q · filed 2025-10-30 | ||||||
| 2024-06-30 | $11.00M 10-Q · filed 2025-07-31 | $21.00M 10-Q · filed 2025-07-31 | ||||||
| 2024-03-31 | $10.00M 10-Q · filed 2025-04-24 | |||||||
| 2023-12-31 | $9.00M 10-K · filed 2026-02-11 | |||||||
| 2023-09-30 | $3.00M 10-Q · filed 2024-10-31 | $9.00M 10-Q · filed 2024-10-31 | ||||||
| 2023-06-30 | $0.00 10-Q · filed 2024-07-26 | $6.00M 10-Q · filed 2024-07-26 | ||||||
| 2023-03-31 | $5.00M 10-Q · filed 2024-04-25 | |||||||
| 2022-12-31 | $80.00M 10-K · filed 2025-02-12 | |||||||
| 2022-09-30 | $64.00M 10-Q · filed 2023-10-26 | $70.00M 10-Q · filed 2023-10-26 | ||||||
| 2022-06-30 | $0.00 10-Q · filed 2023-07-27 | $6.00M 10-Q · filed 2023-07-27 | ||||||
| 2022-03-31 | $6.00M 10-Q · filed 2023-04-27 | |||||||
| 2021-12-31 | $918.00M 10-K · filed 2024-02-13 | |||||||
| 2021-09-30 | $447.00M 10-Q · filed 2022-10-26 | $908.00M 10-Q · filed 2022-10-26 | ||||||
| 2021-06-30 | $192.00M 10-Q · filed 2022-07-27 | $99.00M 10-Q · filed 2021-07-28 | $461.00M 10-Q · filed 2022-07-27 | $130.00M 10-Q · filed 2021-07-28 | ||||
| 2021-03-31 | $269.00M 10-Q · filed 2022-04-29 | $31.00M 10-Q · filed 2021-04-29 | ||||||
| 2020-12-31 | $388.00M 10-K · filed 2023-02-14 | $183.00M 10-K · filed 2021-02-10 | ||||||
| 2020-09-30 | $46.00M 10-Q · filed 2021-10-27 | $319.00M 10-Q · filed 2021-10-27 | $318.00M 10-Q · filed 2020-11-05 | |||||
| 2020-06-30 | $55.00M 10-Q · filed 2021-07-28 | $197.00M 10-Q · filed 2020-08-06 | $130.00M 10-Q · filed 2021-07-28 | $272.00M 10-Q · filed 2020-08-06 | ||||
| 2020-03-31 | $75.00M 10-Q · filed 2021-04-29 | |||||||
| 2019-12-31 | $58.00M 10-K · filed 2022-02-09 | |||||||
| 2018-12-31 | $19.00M 10-K · filed 2021-02-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |